- Home
- GCI vs XERS Comparison
GCI vs XERS Comparison
Compare GCI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- XERS
- Stock Information
- Founded
- GCI 1997
- XERS 2005
- Country
- GCI United States
- XERS United States
- Employees
- GCI N/A
- XERS N/A
- Industry
- GCI Newspapers/Magazines
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- XERS Health Care
- Exchange
- GCI Nasdaq
- XERS Nasdaq
- Market Cap
- GCI 549.7M
- XERS 526.3M
- IPO Year
- GCI N/A
- XERS 2018
- Fundamental
- Price
- GCI $3.00
- XERS $4.56
- Analyst Decision
- GCI Buy
- XERS Strong Buy
- Analyst Count
- GCI 3
- XERS 6
- Target Price
- GCI $5.70
- XERS $5.92
- AVG Volume (30 Days)
- GCI 1.6M
- XERS 3.0M
- Earning Date
- GCI 05-01-2025
- XERS 03-06-2025
- Dividend Yield
- GCI N/A
- XERS N/A
- EPS Growth
- GCI N/A
- XERS N/A
- EPS
- GCI N/A
- XERS N/A
- Revenue
- GCI $2,509,315,000.00
- XERS $203,070,000.00
- Revenue This Year
- GCI N/A
- XERS $20.47
- Revenue Next Year
- GCI N/A
- XERS $19.35
- P/E Ratio
- GCI N/A
- XERS N/A
- Revenue Growth
- GCI N/A
- XERS 23.89
- 52 Week Low
- GCI $1.97
- XERS $1.69
- 52 Week High
- GCI $5.93
- XERS $4.68
- Technical
- Relative Strength Index (RSI)
- GCI 18.15
- XERS 70.73
- Support Level
- GCI $3.10
- XERS $4.33
- Resistance Level
- GCI $4.09
- XERS $4.68
- Average True Range (ATR)
- GCI 0.21
- XERS 0.26
- MACD
- GCI -0.08
- XERS 0.08
- Stochastic Oscillator
- GCI 1.81
- XERS 89.09
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.